Brief: Zealand Pharma Announces Positive Phase 2 Zupreme-2 Topline Results For Amylin Analog Petrelintide In People With Overweight Or Obesity And Type 2 Diabetes
07/10/2026 18:17
BRIEF-Zealand Pharma Announces Positive Phase 2 Zupreme-2 Topline Results For Amylin Analog Petrelintide In People With Overweight Or Obesity And Type 2 Diabetes Oct 7 (Reuters) - Zealand Pharma A/S ZELA.CO:
REG-ZEALAND PHARMA ANNOUNCES POSITIVE PHASE 2 ZUPREME-2 TOPLINE RESULTS FOR AMYLIN ANALOG PETRELINTIDE IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES
ZEALAND PHARMA - CO AND ROCHE INITIATE PHASE 3A PROGRAM FOR PETRELINTIDE
Source text: ID:nGNEbDncXs
Further company coverage: ZELA.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)